Genz 644282

Drug Profile

Genz 644282

Alternative Names: Genz-644282

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 21 Dec 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
  • 14 Mar 2013 Genzyme Corporation completed a phase I trial in solid tumours (late-stage disease) in USA (NCT00942799)
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top